NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $6.94 +0.14 (+2.06%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$6.92 -0.03 (-0.36%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Artiva Biotherapeutics Stock (NASDAQ:ARTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$6.77▼$7.1450-Day Range$6.79▼$11.9452-Week Range$2.71▼$14.53Volume275,933 shsAverage Volume541,991 shsMarket Capitalization$339.30 millionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingModerate Buy Company Overview Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient. Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis. The company is also studying its NK cell platform in hematologic malignancies and other diseases in which targeted depletion of abnormal or harmful B cells may have therapeutic value. Artiva is based in San Diego, California, and is focused on advancing its cell therapy candidates through clinical development and toward potential commercialization. Its programs remain investigational and have not been approved by regulatory authorities for general use.AI Generated. May Contain Errors. Read More Artiva Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreARTV MarketRank™: Artiva Biotherapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 323rd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingArtiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialArtiva Biotherapeutics has a consensus price target of $39.00, representing about 462.0% upside from its current price of $6.94.Amount of Analyst CoverageArtiva Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Artiva Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Artiva Biotherapeutics are expected to decrease in the coming year, from ($2.62) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artiva Biotherapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artiva Biotherapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtiva Biotherapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Artiva Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.78% of the float of Artiva Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArtiva Biotherapeutics has a short interest ratio ("days to cover") of 3.67, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artiva Biotherapeutics has recently increased by 11.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.10 News SentimentArtiva Biotherapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Artiva Biotherapeutics this week, compared to 5 articles on an average week.Search Interest7 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $2,559,690.00 in company stock, which represents 0.7544% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have bought 235.66% more of their company's stock than they have sold. Specifically, they have bought $3,645,857.00 in company stock and sold $1,086,167.00 in company stock.Percentage Held by Insiders1.80% of the stock of Artiva Biotherapeutics is held by insiders.Percentage Held by InstitutionsArtiva Biotherapeutics has minimal institutional ownership at this time.Read more about Artiva Biotherapeutics' insider trading history. Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTV Stock News HeadlinesArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Fred Aslan Sells 23,463 SharesOctober 9 at 5:24 AM | americanbankingnews.comInsider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $168,933.60 in StockOctober 8 at 6:07 AM | insidertrades.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Artiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Christopher Horan Sells 10,340 SharesOctober 8 at 5:22 AM | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Jennifer Bush Sells 8,370 SharesOctober 8 at 5:22 AM | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock: Insider Fred Aslan Sells 61,696 SharesOctober 8 at 4:39 AM | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) COO Sells 8,370 Shares of Company StockOctober 7 at 5:37 AM | insidertrades.comArtiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $255,844.68 in StockSeptember 10, 2026 | insidertrades.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $4.29 at the start of the year. Since then, ARTV shares have increased by 61.8% and is now trading at $6.94. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.00. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $209 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at $14.00-$16.00 per share. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artiva Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI). Company Calendar Last Earnings8/06/2026Today10/10/2026American College of Rheumatology (ACR) Convergence 202611/09/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARTV's financial health is in the Green zone, according to TradeSmith. ARTV has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees115Year Founded2019Price Target and Rating Average Price Target for Artiva Biotherapeutics$39.00 High Price Target$41.00 Low Price Target$35.00 Potential Upside/Downside+462.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.86% Return on Assets-48.16% Debt Debt-to-Equity RatioN/A Current Ratio24.16 Quick Ratio24.16 Sales & Book Value Annual Sales$250 thousand Price / Sales1,357.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book1.55Miscellaneous Outstanding Shares48,890,000Free Float48,010,000Market Cap$339.30 million OptionableN/A Beta2.40 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ARTV) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredMy next big call (under $1)On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup r...Crypto 101 Media | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts